EP Patent

EP4132536A1 — Methods for the treatment of headache disorders

Assigned to Boehringer Ingelheim International GmbH · Expires 2023-02-15 · 3y expired

What this patent protects

SGLT2 inhibitors, in particular empagliflozin, can be used in methods for the treatment of headache disorders.

USPTO Abstract

SGLT2 inhibitors, in particular empagliflozin, can be used in methods for the treatment of headache disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4132536A1
Jurisdiction
EP
Classification
—
Expires
2023-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.